Ignite Creation Date:
2024-07-17 @ 10:58 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06462924
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-05-30
Brief Title:
Feasibility of Gadolinium Contrast Reduced Brain MRI the Potential of Deep Learning
Sponsor:
DeepMeds
Organization:
DeepMeds
Study Overview
Official Title:
Feasibility of Gadolinium Contrast Reduced Brain MRI the Potential of Deep Learning
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MRI scans were performed using 3 different 15T scanners with an eight-channel head coils Following a 3D pre-contrast T1w scan a low-dose contrast-enhanced 3D T1w scan was obtained using 20 002 mmolkg of the standard dosage of gadoterate meglumine
The subjects were immediately administered the remaining 80 008 mmolkg of the contrast agent to reach the standard dose of 01 mmolkg which served as a training ground truth for further quantitative assessment All three acquisitions were performed during a single imaging session with no additional gadolinium dose administered above the standard protocol
The subjects were immediately administered the remaining 80 008 mmolkg of the contrast agent to reach the standard dose of 01 mmolkg which served as a training ground truth for further quantitative assessment All three acquisitions were performed during a single imaging session with no additional gadolinium dose administered above the standard protocol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None